

Ute-Christiane Meier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6624928/publications.pdf>

Version: 2024-02-01

51
papers

7,507
citations

201674

27
h-index

233421

45
g-index

54
all docs

54
docs citations

54
times ranked

17320
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D levels in children and adolescents with chronic tic disorders: a multicentre study. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 1-12.	4.7	12
2	A role for pathogen risk factors and autoimmunity in encephalitis lethargica?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110276.	4.8	2
3	<i>Mycoplasma pneumoniae</i> IgG positivity is associated with tic severity in chronic tic disorders. <i>Brain, Behavior, and Immunity</i> , 2021, 99, 281-288.	4.1	6
4	Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. <i>Frontiers in Immunology</i> , 2021, 12, 757302.	4.8	27
5	Risk of Schizophrenia and Bipolar Disorder in Patients With Multiple Sclerosis: Record-Linkage Studies. <i>Frontiers in Psychiatry</i> , 2020, 11, 662.	2.6	8
6	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 91-109.	4.7	36
7	Pronounced immunological abnormalities in unmedicated first episode as compared to chronic schizophrenia patients. <i>Neurology Psychiatry and Brain Research</i> , 2019, 34, 58-63.	2.0	0
8	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 123-128.	2.0	25
9	Prodromal symptoms of multiple sclerosis in primary care. <i>Annals of Neurology</i> , 2018, 83, 1162-1173.	5.3	98
10	Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 46-50.	2.0	18
11	Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. <i>Journal of Neuroimmunology</i> , 2017, 306, 40-45.	2.3	17
12	Seasonal temperature is associated with Parkinson's disease prescriptions: an ecological study. <i>International Journal of Biometeorology</i> , 2017, 61, 2205-2211.	3.0	6
13	Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism. <i>Frontiers in Psychiatry</i> , 2017, 8, 47.	2.6	59
14	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnp-2014-309690.	1.9	90
15	Early changes within the lymphocyte population are associated with the development of multiple organ dysfunction syndrome in trauma patients. <i>Critical Care</i> , 2016, 20, 176.	5.8	51
16	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
17	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	3.0	249
18	Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. <i>Biosensors and Bioelectronics</i> , 2015, 68, 660-667.	10.1	69

#	ARTICLE	IF	CITATIONS
19	Unaltered frequency and functionality of CD56bright and CD56dim natural killer cells in untreated relapsingâ€“remitting multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014, 275, 46.	2.3	0
20	Detection of antibodies against the N-methyl-d-aspartate receptor in a sub-group of patients diagnosed with Tourette's syndrome. <i>Journal of Neuroimmunology</i> , 2014, 275, 98.	2.3	1
21	Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort. <i>Multiple Sclerosis Journal</i> , 2014, 20, 751-753.	3.0	14
22	Epsteinâ€“Barr virus, latitude and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 362-365.	3.0	30
23	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 162-166.	3.0	139
24	Month of Birth and Thymic Output. <i>JAMA Neurology</i> , 2013, 70, 527.	9.0	19
25	Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf. <i>Journal of Immunology</i> , 2013, 190, 58-65.	0.8	57
26	Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. <i>Neurology</i> , 2012, 78, 15-23.	1.1	119
27	131â€“Do siblings of people with multiple sclerosis (MS) have markers of MS risk?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, e1.83-e1.	1.9	0
28	Cell death pathways and autophagy in the central nervous system and its involvement in neurodegeneration, immunity and central nervous system infection: to die or not to die - that is the question. <i>Clinical and Experimental Immunology</i> , 2012, 168, 52-57.	2.6	49
29	Can latent Epstein-Barr virus infection in the central nervous system contribute to neuroinflammation?. <i>Neurology Psychiatry and Brain Research</i> , 2012, 18, 71.	2.0	0
30	Vitamin D: a link between Epsteinâ€“Barr virus and multiple sclerosis development?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1221-1224.	2.8	21
31	Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. <i>Pathophysiology</i> , 2011, 18, 13-20.	2.2	19
32	More to come: Humoral immune responses in MS. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 13-21.	2.3	7
33	Vitamin D deficiencyâ€“do we follow our own advice?. <i>Clinical Medicine</i> , 2011, 11, 521-523.	1.9	0
34	Role of the HLA System in the Association Between Multiple Sclerosis and Infectious Mononucleosis. <i>Archives of Neurology</i> , 2011, 68, 469.	4.5	17
35	Epstein-Barr virus in the multiple sclerosis brain: a controversial issueâ€“report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. <i>Brain</i> , 2011, 134, 2772-2786.	7.6	176
36	Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epsteinâ€“Barr virus entry to the central nervous system?. <i>Clinical and Experimental Immunology</i> , 2011, 167, 1-6.	2.6	37

#	ARTICLE	IF	CITATIONS
37	Epstein-Barr Virus and Multiple Sclerosis. , 2011, , 25-37.		1
38	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. <i>Lancet Neurology</i> , The, 2010, 9, 727-739.	10.2	459
39	Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. <i>Brain</i> , 2010, 133, e137-e137.	7.6	132
40	Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in Multiple Sclerosis and EAE. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 738-746.	4.1	41
41	Regulation of autoimmune encephalomyelitis by toll-like receptors. <i>Autoimmunity Reviews</i> , 2009, 8, 506-509.	5.8	69
42	Th1 Polarization of CD4+ T Cells by Toll-Like Receptor 3-Activated Human Microglia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 848-859.	1.7	30
43	Shared Alterations in NK Cell Frequency, Phenotype, and Function in Chronic Human Immunodeficiency Virus and Hepatitis C Virus Infections. <i>Journal of Virology</i> , 2005, 79, 12365-12374.	3.4	161
44	Frequency and Phenotype of Circulating $\hat{V}124/\hat{V}211$ Double-Positive Natural Killer T Cells during Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2003, 77, 2251-2257.	3.4	101
45	A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using $\hat{I}23$ Domain Mutants of MHC Class I/Peptide Complex. <i>Immunity</i> , 2001, 14, 591-602.	14.3	70
46	Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide- $\hat{I}22m$ fusion molecules. <i>European Journal of Immunology</i> , 2001, 31, 440-449.	2.9	28
47	The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. <i>Journal of Molecular Medicine</i> , 1998, 76, 699-708.	3.9	37
48	The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. <i>European Journal of Immunology</i> , 1995, 25, 1927-1931.	2.9	75
49	Cytotoxic T Lymphocyte Lysis Inhibited by Viable HIV Mutants. <i>Science</i> , 1995, 270, 1360-1362.	12.6	107
50	The Cleavage of the Bait Region of $\hat{I}2$ -Macroglobulin by Human Immunodeficiency Virus Proteinases and by Astacin. <i>Annals of the New York Academy of Sciences</i> , 1994, 737, 431-433.	3.8	5
51	$\hat{I}2$ -Macroglobulin is Cleaved by HIV-1 Protease in the Bait Region but not in the C-Terminal Inter-Domain Region. <i>Biological Chemistry Hoppe-Seyler</i> , 1991, 372, 1051-1056.	1.4	12